Navigation Links
JDRF, Pfizer, Hadassah Medical and the Hebrew University announce collaboration

NEW YORK, March 22, 2010 The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, said today that it will begin a diabetes research collaboration with Pfizer, Hadassah Medical Organization, and The Hebrew University of Jerusalem on drugs to replicate and regenerate insulin-producing cells in people with type 1 diabetes.

The program, under the direction of Professor Benjamin Glaser (Hadassah Medical) and Dr. Yuval Dor (Department of Developmental Biology, Institute for Medical Research Israel-Canada (IMRIC) at The Hebrew University), and in collaboration with scientists from Pfizer PharmaTherapeutics Research & Development, is jointly funded by JDRF and Pfizer.

The research team will focus on the preclinical evaluation of certain proprietary Pfizer compounds as candidates to promote beta cell replication and regeneration. Drugs that can stimulate beta cell replication and expand beta cell mass have potential as disease-modifying agents for the treatment of insulin-dependent diabetes.

The collaboration aims to provide a comprehensive biological characterization of the Pfizer compounds' potential beneficial effect on beta cell health and survival, building on unique beta cell regeneration models created by Dr. Dor and funded in part by JDRF.

"Drugs that can stimulate the replication of insulin-producing cells and expand beta cell mass have the potential to reverse type 1 diabetes," said Alan J. Lewis, Ph.D., President and Chief Executive Officer of JDRF. "This program may accelerate one of JDRF's key research goals: to find ways to restore the body's ability to make insulin."

"With this collaboration, Pfizer, Hadassah Medical Organization, The Hebrew University of Jerusalem and the JDRF are creating a unique model for how clinical and biomedical scientists in industry and academia, in collaboration with non-profit organizations, can work together for the benefit of patients." said Tim Rolph, PhD., Vice President of Pfizer's Cardiovascular Metabolic and Endocrine Diseases Research. "Each group brings to the table its specific set of skills and expertise to address complex problems that each alone would take much longer to solve."

"We are very excited about this program and the close collaboration with JDRF and Pfizer," said Dr. Dor. "Ben Glaser and myself have put considerable efforts in recent years into understanding the basic mechanisms by which the total number of beta cells in healthy adult organisms is regulated, and what triggers the formation of new beta cells when demand exceeds supply. With this new project we are given a chance to examine if our insights can be utilized, using clinically relevant drugs supplied by Pfizer, for boosting beta cell mass in healthy and diabetic mice."


Contact: Joana Casas
Juvenile Diabetes Research Foundation International

Related biology news :

1. American College of Medical Genetics responds to new FDA labeling decision for warfarin
2. M2SYS Partners With Gnosis Medical Services to Provide Accurate Patient Identification in Developing Countries Through Innovative Biometrics Solution
3. Boston University biomedical engineers find chink in bacterias armor
4. $22 million gift from Alfred Taubman launches new biomedical research institute
5. USC biomedical team to participate in $6 million low vision project
6. 3 Columbia University Medical Center faculty elected to Institute of Medicine
7. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
8. UMass Medical School researchers receive $8.5M grant award to fight AIDS
9. Natural product discovery by Cleveland medical researchers blocks tissue destruction
10. Triage study challenges notions of emergency medical response to disaster
11. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
Post Your Comments:
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
Breaking Biology Technology: